| 19.32 1.77 (10.09%) | 04-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.27 | 1-year : | 26.86 |
| Resists | First : | 20.78 | Second : | 23 |
| Pivot price | 19.93  |
|||
| Supports | First : | 17.2 | Second : | 14.31 |
| MAs | MA(5) : | 18.33 |
MA(20) : | 20.36 |
| MA(100) : | 24.93 |
MA(250) : | 21.4 |
|
| MACD | MACD : | -1.1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 17.3 |
D(3) : | 12.7 |
| RSI | RSI(14): 44.1 |
|||
| 52-week | High : | 44.59 | Low : | 8.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZBIO ] has closed above bottom band by 39.1%. Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 19.5 - 19.61 | 19.61 - 19.71 |
| Low: | 17.92 - 18.06 | 18.06 - 18.19 |
| Close: | 19.11 - 19.32 | 19.32 - 19.51 |
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Fri, 01 May 2026
Zenas BioPharma (ZBIO) Price Target Increased by 21.59% to 40.22 - MSN
Thu, 30 Apr 2026
Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026 (NASDAQ:ZBIO) - Seeking Alpha
Thu, 30 Apr 2026
Zenas BioPharma rises on CEO insider purchase (ZBIO:NASDAQ) - Seeking Alpha
Wed, 29 Apr 2026
Zenas BioPharma CEO Makes Bold Move With Major Personal Stock Buy - TipRanks
Wed, 29 Apr 2026
Zenas BioPharma CEO Moulder buys $1.07m in ZBIO shares - Investing.com
Wed, 29 Apr 2026
Zenas BioPharma (ZBIO) CEO-linked entities purchase 60,000 shares in open market - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.522e+007 (%) |
| Held by Institutions | 24.5 (%) |
| Shares Short | 8,020 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1133e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 113.8 % |
| Return on Equity (ttm) | -35.1 % |
| Qtrly Rev. Growth | 1e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -8.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -172 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 9.36e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|